Crescent Biopharma (CBIO) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for June 2, 2026, with virtual participation available.

• Shareholders are invited to vote on key proposals, including director election, auditor ratification, and executive compensation.

Voting matters and shareholder proposals

• Election of Susan Moran, M.D., MSCE as Class II Director for a term expiring at the 2029 Annual General Meeting.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote to approve named executive officers' compensation.

• Advisory vote on the frequency of future say-on-pay votes, with a recommendation for annual votes.

• Provision for other business to be addressed as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director election and auditor ratification.